Stock SRTOY SARTORIUS STEDIM BIOTECH S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Sartorius Stedim Biotech S.A. OTC Markets

Equities

SRTOY

US80386Y1010

Market Closed - OTC Markets
Other stock markets
 07:50:05 14/06/2024 pm IST 		5-day change 1st Jan Change
19 USD -2.56% Intraday chart for Sartorius Stedim Biotech S.A. -7.95% -30.73%
03/06 SARTORIUS STEDIM BIOTECH : EPS cut (2023: -13.7%, 2024: -16.4%) Alphavalue
16/05 Sartorius sinks again towards year low DP

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • With an expected P/E ratio at 50.31 and 36.16 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SARTORIUS STEDIM BIOTECH S.A. Stock Sartorius Stedim Biotech S.A.
-30.73% 1.86TCr -
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.81% 18TCr
C+
MEDTRONIC PLC Stock Medtronic plc
-1.63% 11TCr
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.14% 6.75TCr
A
DEXCOM, INC. Stock DexCom, Inc.
-6.56% 4.61TCr
B-
CENCORA, INC. Stock Cencora, Inc.
+13.22% 4.58TCr
B-
HOYA CORPORATION Stock Hoya Corporation
+6.13% 4.16TCr
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+19.93% 3.11TCr
B
TERUMO CORPORATION Stock Terumo Corporation
+13.61% 2.48TCr
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-5.36% 2.43TCr
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DIM Stock
  4. SRTOY Stock
  5. Ratings Sartorius Stedim Biotech S.A.